Although direct sequencing of UBE2QL1 in 17 RCC cell lines and 116 sporadic RCC did not detect intragenic mutations, analysis for copy number abnormalities using a custom-designed MLPA assay detected heterozygous UBE2QL1 deletions in 8/49 (16.3%) sporadic RCC (Fig. 2B). This evidence concerns the gene UBE2QL1 and renal cell carcinoma.